Differential Effects of Morphine‐6‐glucuronide, an Active Metabolite of Morphine, and Morphine on Locomotor Activity in Mice: Involvement of the Opioid Receptor

Authors:

Abstract
Subcutaneous administration of morphine (2.5 to 20 mg/kg) or an active metabolite of morphine, morphine‐6‐glucuronide (2.5 to 20 mg/kg), increased the locomotor activity of mice in a dose‐dependent manner. Fifteen mg/kg of morphine and 20 mg/kg of morphine‐6‐glucuronide were almost equipotent. Subcutaneous administration of the universal opioid antagonist, naloxone, but not the δ‐selective antagonist, naltrindole, significantly suppressed the hyperlocomotion induced by morphine (15 mg/kg). On the other hand the subcutaneous administration of relatively higher doses of naloxone or naltrindole significantly reduced the hyperlocomotion induced by morphine‐6‐glucuronide (20 mg/kg). These findings suggest that agonistic actions at the opioid receptors, especially at the δ‐ and μ‐receptors, contribute to the morphine‐6‐glucuronide‐induced hyperlocomotion.

This publication has 13 references indexed in Scilit: